NCT07498933Recruiting
FAP-targeted PET/NIR in Lung Malignant Tumors
Visualization Study on Tumor Progression Mechanisms and Key Molecular Functions in Neoadjuvant Immunotherapy for Lung Cancer: Preoperative Efficacy Prediction and Intraoperative Fluorescence Navigation
Source: ClinicalTrials.gov · Last updated 1 Apr 2026
Brief summary (registry, in English)
Single center, prospective, diagnostic study. Patients with stage II-IIIB resectable NSCLC diagnosed by pathology were included. After receiving standard neoadjuvant therapy (chemotherapy/immunotherapy/combination therapy), FAPI-PET/CT and fluorescence imaging were performed one week before surgery. During the surgery, a near-infrared fluorescence navigation system was used to locate the tumor lesion. After surgery, the tumor bed range was determined by pathological gold standards (HE staining+immunohistochemistry), and the predictive efficacy and localization accuracy of FAPI-PET/fluorescence were compared and analyzed.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 200 (estimated)
- First submitted
- 23 Mar 2026
- Start date
- 3 Jun 2025
- Primary completion date
- 31 Oct 2027
- Lead sponsor
- Peking University People's Hospital
- Diseases
- Lung cancer
- NCT number
- NCT07498933
What you commit to
- Study type: Observational
- Planned participants: 200
- From 3 Jun 2025 to the primary completion date, 31 Oct 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previously combined with other malignant tumors or received other anti-tumor treatments;
- The duration of neoadjuvant therapy is less than 3 cycles;
Other illness
- Failure to collect sufficient tumor tissue for testing and research;
Other
- The dynamic scanning image quality of multimodal probe PET cannot meet the analysis standards or is missing;
- Lack of clinical and imaging data;
- There are situations where other researchers consider it inappropriate to participate in this study
Who the study is looking for
- Age between 18 and 70 years old;
- Have complete clinical and imaging data;
- Prior to neoadjuvant therapy, the biopsy pathology showed lung cancer;
- Able to retain sufficient tumor tissue for testing and research;
- Sign informed consent.
Age in the registry: 18 years to 70 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Peking University People's Hospital Coordinator of this site? Confirm its status | Beijing | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.